BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, June 17, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Hepaitech (Beijing) Biopharma Technology discovers MRGPRX4 antagonists
To read the full story,
subscribe
or
sign in
.
Infection
Hepaitech (Beijing) Biopharma Technology discovers MRGPRX4 antagonists
May 16, 2024
Hepaitech (Beijing) Biopharma Technology Co. Ltd. has patented compounds reported to be useful for the treatment of anemia, fungal infections and HIV infections, among others.
BioWorld Science
Infection
Patents